Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Sotera Health (SHC)

Sotera Health Q1 revenue up 2.6% to $255 million; net loss of $13 million

Mixed Impact 3 of 5 earnings Written later

Sotera Health reported first-quarter 2025 net revenues up 2.6% to $255 million and Adjusted EBITDA up 8.8% to $122 million, but a net loss of $13 million, or $0.05 per diluted share, after an approximately $31 million EO claims settlement against Sterigenics. The company reaffirmed its full-year 2025 outlook for net revenue growth of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5%, on a constant currency basis.

Key points

  • Net revenues rose 2.6% to $255 million (4.4% on a constant currency basis) versus Q1 2024.
  • Net loss of $13 million, or $0.05 per diluted share, compared with net income of $6 million, or $0.02, in Q1 2024; includes an approximately $31 million Illinois EO litigation settlement.
  • Adjusted EBITDA rose 8.8% to $122 million; Adjusted EPS was $0.14, up $0.01 from $0.13.
  • 2025 outlook reaffirmed: net revenue growth of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5%, constant currency; Adjusted EPS of $0.70 to $0.76.

The filing

CompanySotera Health (SHC)
Form8-K, current report
Filed with the SECMay 1, 2025, 7:45 AM ET
Accession number0001822479-25-000022

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:00 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.